Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Rezolute, Inc. (RZLT : NSDQ)

• Company Description    Rezolute, Inc. is a biopharmaceutical company specializing in the development of drug therapies for metabolic and orphan diseases. The Company's products include AB101, RZ358, RZ402 and RZ602 which are in clinical stage. Rezolute, Inc., formerly known as AntriaBio, Inc., is based in LOUISVILLE, United States. Number of Employees: 71

• Price / Volume Information    Yesterday's Closing Price: $9.00 Daily Weekly Monthly 20 Day Moving Average: 1,699,829 shares Shares Outstanding: 90.83 (millions) Market Capitalization: $817.45 (millions) Beta: 0.04 52 Week High: $9.72 52 Week Low: $2.22 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 16.73% 15.49% 12 Week 53.06% 45.90% Year To Date 83.67% 61.94%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 275 SHORELINE DRIVE SUITE 500 - REDWOOD CITY,CA 94065 USA ph: 650-206-4507 fax: - investor-relations@rezolutebio.com http://www.rezolutebio.com

• General Corporate Information    Officers Nevan Charles Elam - Chairman of the Board of Directors and Chief Execu Erik Harris - Director Gil Labrucherie - Director Nerissa Kreher - Director Philippe Fauchet - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 76200L309 SIC: 2834 Fiscal Year Fiscal Year End: June Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 90.83 Most Recent Split Date: 10.00 (0.02:1) Beta: 0.04 Market Capitalization: $817.45 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.28 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.06 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.83 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 40.91% vs. Previous Quarter: 3.70% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -65.03 03/31/25 - -70.09 ROA 09/30/25 - - 06/30/25 - -58.86 03/31/25 - -63.08 Current Ratio 09/30/25 - - 06/30/25 - 14.37 03/31/25 - 8.43 Quick Ratio 09/30/25 - - 06/30/25 - 14.37 03/31/25 - 8.43 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 1.86 03/31/25 - 1.36 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©